China Everbright Healthcare Fund To Buy Ambrx

A group of companies led by China Everbright’s healthcare company is buying Ambrx, a U.S. biotechnology firm, for an unknown amount.

Announced Friday morning, the deal includes major Mainland Chinese healthcare companies including Shanghai Fosun Pharmaceutical and WuXi PharmaTech, and investment firm HOPU investments. The transaction, which will need regulatory approval, may be completed by the second quarter.